• The Journal of Internal Korean Medicine
• /
• v.42 no.5
• /
• pp.976-981
• /
• 2021

Objectives: This study investigated the effectiveness of acupuncture for improving polycythemia-vera-related symptoms and quality of life. Methods: A 56-year-old woman diagnosed with polycythemia vera received acupuncture treatment between February 19, 2021, and August 26, 2021. We observed the changes in subjective symptoms and conducted myeloproliferative neoplasm symptom assessment form total symptom score (MPN-SAF TSS) questionnaire. Results: After 13 acupuncture treatment sessions over six months, symptoms of polycythemia vera, such as fatigue, bone pain, itching, and headache, improved. Conclusion: This study suggests that acupuncture may be a helpful treatment strategy for polycythemia vera patients suffering from significant symptom burdens and reduced quality of life.

• The Journal of Internal Korean Medicine
• /
• v.41 no.6
• /
• pp.1265-1273
• /
• 2020

Objectives: Patients with polycythemia vera can experience many symptoms, including dizziness, headache, and fatigue, caused by a high red blood cell mass and blood viscosity. Some symptoms persist even after appropriate treatment. The purpose of this study was to examine the effect of Korean medicine on dizziness following polycythemia vera treatment. Methods: A patient diagnosed with polycythemia vera was treated with Korean medicine, including pharmacopuncture, acupuncture, and herbal medicine. We used a numeral rating scale (NRS) and the Dizziness Handicap Inventory (DHI) to observe the effects of the treatment. Results: After treatment, the hematocrit and hemoglobin increased to within normal range, and the NRS scores for dizziness and fatigue, subjective discomfort, and DHI scores decreased compared with the preadmission values. Conclusions: This report shows that Korean medicine helped to relieve dizziness in a patient with polycythemia vera. However, we need further studies to establish treatment regimens for polycythemia vera symptoms.

• Journal of Korean Traditional Oncology
• /
• v.15 no.1
• /
• pp.105-110
• /
• 2010

Objective: This study reports one case of polycythemia vera patient treated with oriental medicine in conjunction with conventional medicine. Methods: One patient who was diagnosed with polycythemia vera was treated using different modalities of herbs, acupuncture, and pharmacopuncture. An herbal formula, Yongdamsagan-tang was given three times a day with daily acupuncture treatment session, in addition to Soyeom and Jahageo pharmacopuncture injection which were administered three times a week. After treatment, patient's symptoms and blood test results were observed and analyzed. Results: After ten days of treatment, the patient had shown improvements in symptoms of headache, dizziness, tinnitus, and itchiness. Two months later, laboratory findings continued to be kept within the normal range and the intervals of phlebotomy therapy has extended to three months. Conclusions: This case study shows minimum evidence of safety and efficacy of oriental medicine for managing symptoms of polycythemia vera. Considering this is only a short term, single case study, further research is needed to confirm these results.

• Journal of the Korean Association of Oral and Maxillofacial Surgeons
• /
• v.35 no.6
• /
• pp.459-461
• /
• 2009

Polycythemia vera is one type of myeloproliferative disorder which occurs due to the clonal proliferation of hematopoietic stem cell related to the production of leukocyte and megakaryocyte which produces a little less than erythrocyte. Polycythemia vera has a peak incidence in the sixth decade of life with males affected slightly more frequently than females. Vasquez first described polycythemia vera as an autonomous erythrocytosis in 1892, and a further description, delineation of the disease process and a complete course outline were made in 1899, 1903 and 1938, respectively. Symptoms include pruritus, tinnitus, vertigo, gastrointestinal (GI) pain, and bleeding gums. Hyperuricemia and hyperuricosuria are present in about 40% of these patients. Complications are hemorrhage, thrombosis, post-polycythemic myeloid metaplasia, and leukemic transformation. In case of surgery, complications such as hemorrahge and thrombosis are highly likable to happen. We report a case of preoperative and postoperative of a 63-year-old male, who was diagnosed as oral cavity cancer in the mouth floor, with known history of hypertension and polycythemia vera. We considered that conservative management would be an advisable treatment for patients with uncontrolled systemic disease.

• Journal of Korean Neurosurgical Society
• /
• v.58 no.2
• /
• pp.137-140
• /
• 2015

The most common neurologic manifestations of polycythemia vera (PV) are cerebral infarction and transient ischemic attacks, while cerebral hemorrhage or intracranial dissection has been rarely associated with PV. Here we report the first case of a 59-year-old patient with intracranial supraclinoid internal carotid artery (ICA) dissection causing cerebral infarction and concomitant subarachnoid hemorrhage due to pseudoaneurysm rupture as clinical onset of PV. This case report discusses the possible mechanism and treatment of this extremely rare condition.

• Asian Pacific Journal of Cancer Prevention
• /
• v.15 no.4
• /
• pp.1681-1684
• /
• 2014

Objective: To investigate interferon (IFN) alpha 2 b for treating patients with JAK2V617F positive polycythemia vera (PV) and essential thrombocytosis (ET). Methods: Interferon alpha 2 b was used to treat patients with JAK2V617F positive PV and ET. In control group, hydroxyurea was used. Endpoint of study was to compare rates of hematological and molecular remission. Results: Patients in the interferon alpha 2 b group achieved higher rates of hematologic and molecular remission than patients in the hydroxyurea group, with a lower incidence of thrombosis. Conclusion: Compared with hydroxyurea, interferon alpha 2 b could reduce JAK2V617F load for patients with PV and ET, and achieve higher molecular remission, improve treatment efficacy and reduce complications.

• Journal of Yeungnam Medical Science
• /
• v.6 no.2
• /
• pp.247-255
• /
• 1989

We report a case of polycythemia vera combined with coagulation disorder. The patient was 54 years old man who complained of continuous bleeding after incision of skin abscess 20days ago. Laboratory tests were revealed prolonged aPTT and slightly prolonged PT. Coagulation factor, I, VIII, IX, XI and fibrinogen decreased, however FDP did not increased. It appears that patient with polycythemia vera have chronic activation of coagulation system, probably initiated by activation of factor XII. Platelet aggregation test to ADP, collagen, epinephrine was also revealed poor response.

• Journal of Yeungnam Medical Science
• /
• v.26 no.1
• /
• pp.44-48
• /
• 2009

Talus tuberculosis is a rare disease, even in an endemic tuberculosis area. In reviews of the worldwide literature, only 18 cases of talus tuberculosis have been reported. Recently, we experienced a case of a 70-year-old polycythemia vera patient with right metatarsopharyngeal joint pain for 2 months duration who was diagnosed with talus tuberculosis with prostate involvement. Tuberculosis should be considered as one of the causes of monoarticulitis, especially in countries, where the disease is endemic. Additionally, we highly recommend taking a biopsy of the site of suspected infection because an early diagnosis is the key to successful treatment.

• Annals of Clinical Neurophysiology
• /
• v.17 no.1
• /
• pp.41-43
• /
• 2015

• Asian Pacific Journal of Cancer Prevention
• /
• v.17 no.3
• /
• pp.1053-1055
• /
• 2016

Background: Polycythemia rubra vera (PV), being a primary polycythemia, is caused by neoplastic proliferation of erythroid, megakaryocytic and granulocytic lineages which result in panmyelosis. PV patients have a somatic acquired mutation in the Janus kinase (JAK2) pathway, rendering cell proliferation independent of the normal regulatory mechanisms that regulate erythropoiesis. The rational of this study was to determine the prevalence of the JAK-2 V617F mutation in Pakistani patients with PV. Materials and Methods: In this cross sectional study, 26 patients with PV were enrolled from January 2010 to December 2014. Patients were diagnosed based on WHO criteria for PV. All were screened for G-T point mutation (V617F) in the JAK2 gene on chromosome 9 by an allele specific PCR. Results: The mean age was $53.4{\pm}9.31years$ (range 36-72) and the male to female ratio was 2:1. The frequency of JAK2 V617F positivity in our PV patients was found to be 92.3%. Overall 30.7% of patients were asymptomatic and remaining 69.3% presented with symptomatic disease. The mean hemoglobin was $18.1{\pm}1.9g/dl$ with the mean hematocrit of $55.6{\pm}8.3%$. The mean total leukocyte count was $12.8{\pm}7.1{\times}10^9/l$ and the platelet count was $511{\pm}341.9{\times}10^9/l$. A positive correlation of JAK2 V617F mutation was established with high TLC count (P=0.01). No correlation of JAK2 V617F could be established with age or gender (P>0.05). Conclusions: The JAK2 V617F mutation frequency in our PV patients was similar to those reported internationally. Screening for the mutation in all suspected PV cases could be beneficial in differentiating patients with reactive and clonal erythrocytosis.